Background {#Sec1}
==========

Parkinson disease (PD) is a neurodegenerative disease. Important components of the pathomechanism are protein aggregation and lysosomal as well as mitochondrial dysfunction \[[@CR1]\]. Inflammation has been increasingly recognized as an additional component of the pathomechanism of PD \[[@CR2]\]. Encephalitis mediated by autoantibodies against NMDA-type glutamate receptors (NMDAab) is an important cause of autoimmune encephalitis \[[@CR3]\]. These findings prompted the question whether NMDAab contribute to the inflammatory component of PD. Two previous studies have examined the prevalence of NMDAab in the serum of PD patients. One performed in a large sample of PD patients (*n* = 258) and controls (*n* = 1730) did not find an association of NMDAab with PD \[[@CR4]\]. However, in this study detailed phenotypic characteristics were not reported and the study was criticised for using unselected blood-donors as controls \[[@CR4]\]. The other study included 74 PD patients, 25 of whom were diagnosed as PD with dementia (PD-D) and 47 healthy controls \[[@CR5]\]. This study did not find an association between PD per se and antibody positivity but reported a significantly higher proportion of antibody positive cases in PD patients with dementia compared to PD without dementia \[[@CR5]\].

Landscape is a prospective study using detailed phenotyping to characterize the natural course of PD, especially with respect to dementia. Popgen is a population based study of health in northern Germany. The present study uses serum samples of Landscape and popgen Biobank \[[@CR6]\] as well as samples collected at the Department of Neurology, Kiel University to address three questions: (I) Are IgA/IgM NMDAab associated with PD?; (II) Does the frequency of NMDAab of the IgA/IgM classes differ between PD patients without cognitive impairment and those with cognitive impairment?; (III) Is IgA/IgM NMDAab antibody status correlated with differences in cognitive test results?

Participants and methods {#Sec2}
========================

Participants {#Sec3}
------------

All participants gave written informed consent. Ethics committee approval was obtained for all studies involved (Department of Neurology of Kiel University, Landscape, popgen). Objectives, recruitment and phenotyping procedures in popgen and Landscape have been described in detail elsewhere \[[@CR6], [@CR7]\]. We used the following general metrics: sex, age at examination, age at PD onset, PD duration and Unified Parkinson Disease Rating Scale part III (motor part). Landscape involves a large number of cognitive tests. For this study we analysed the results of the following tests measuring different cognitive domains: Mini-Mental-State-Examination (MMSE) \[[@CR8]\], Parkinson Neuropsychometric Dementia Assessment (PANDA) a test especially developed to assess cognitive deficits in PD \[[@CR9]\], the backwards digit span (working memory, Wechsler Memory Scale revised) and CERAD word list learning and recall (immediate and delayed verbal memory), the Stroop colour word, colour line and interference test, the CERAD plus trail making test A and B (executive function) \[[@CR10]\], the modified Card Sorting Test examining the ability to display flexibility in the face of changing schedules of reinforcement and the Performance Evaluation System for Seniors (LPS 50+) subtest 9 \[[@CR11]\], a German test battery with subtest 9 assessing visuo-spatial skills.

In the Landscape study PD with minimal cognitive impairment (PD-MCI) was defined according to established MCI criteria. These included in short (1) cognitive dysfunction reported by the patient, (2) no significant impairment in daily living and (3) at least one score ≥ 1.5 standard deviations (SD) below normative values in at least one of the tests used for diagnosis by Kalbe et al. \[[@CR12]\]. PD-D was diagnosed using the criteria for possible and probable PD-D by Emre et al. \[[@CR13]\] including (1) cognitive dysfunction reported by the patient or caregiver, (2) significant impairment in daily living and (3) at least two scores ≥1.5 standard deviations (SD) below normative values in two of five different cognitive domains. Features suggesting other conditions or diseases as cause of mental impairment were exclusion criteria for the diagnosis PD-D. This study analysed 296 PD patients (93 from the Departmentof Neurology Kiel University, 203 from the Landscape study) and 295 controls (49 from the Department of Neurology Kiel University, 246 from the popgen study).

Serum samples and phenotypes of Landscape patients were obtained from the central repository at Marburg University. Popgen controls were nearly perfectly matched with respect to sex and age to the patients and serum samples obtained from the popgen biobank at Kiel University \[[@CR6]\]. PD patients and sex as well as approximately age matched controls from the Department of Neurology, Kiel University were prospectively collected exclusively by FH. FH assessed the following phenotypes in PD patients: age, sex, UPDRS III, dementia (no, yes), mild cognitive impairment (MCI, no, yes) by neuropsychiatric examination and via consultation of the clinical records. FH examined the Kiel University controls rendering dementia and severe mood disorders unlikely. All controls were free of self-reported neuropsychiatric disease. All popgen controls underwent a standardized general physical examination by the study physicians and completed questionnaires including screening questions for mood disorders which revealed no evidence for a neuropsychiatric disease or dementia. However, formal neuropsychological testing for dementia was not performed in either control group and mood disorders were not assessed in patients as well as Kiel controls.

Serological analyses {#Sec4}
--------------------

Serum samples of all participants were processed according to previously published, validated procedures also used in both previous studies at Euroimmun, Lübeck, Germany \[[@CR4], [@CR5]\]. Serum was tested at a starting dilution of 1:10 on fixed transfected HEK-cells using FITC labelled goat-anti-human Ig detecting all isoforms. Positive samples were further assessed using Fc-specific anti-human IgG, IgA or IgM and performing serial dilutions according to manufacturer's instructions (Euroimmun). End-point titres were assessed by researchers blinded to clinical data. In addition to NMDAab IgG, IgA and IgM, a number of additional autoantibodies were assessed. None of them was prevalent enough to perform a meaningful statistical analysis (data not shown).

Statistical analyses {#Sec5}
--------------------

All statistical analyses were performed using RStudio (version 1.0.136). Detailed data on NMDAab titres are found in Additional file [1](#MOESM1){ref-type="media"}: Table S1. For comparability with previous studies we regarded all samples with any titre of NMDAab as positive. However, we also performed the analyses regarding only titres \> 1:32 as positive because the value of low NMDAab titres is a matter of debate. Both definitions of NMDAab positivity revealed essentially the same results, meaning that *p*-values changed but none of the insignificant differences between groups became significant or vice versa (data not shown).

For comparison of categorical values between groups, we used the Chi-square test (chi2). Age at examination, age at PD onset and PD duration were compared using Student's t-test (t) for two groups and analysis of variance (ANOVA) for more than two groups. Non-normally distributed interval-scaled or ordinal data were compared using the Mann-Whitney-U test (MWU) for two groups and the Kruskal-Wallis test (KW) for more than two groups. The quantitative relationship between age (exposure) and antibody status (outcome) was assessed using logistic regression (LR) in order to obtain odds-ratios.

Results {#Sec6}
=======

It is now well recognized that NMDAab receptor encephalitis is a separate etiologic entity caused only by specific IgG but not by IgA or IgM NMDAab \[[@CR3]\]. Therefore we excluded IgG NMDAab from the analysis. However, since only one PD and two controls had positive IgG NMDAab, including or excluding them had only extremely minor impact on the results which was far from changing any statistically insignificant differences to significant ones or vice versa (data not shown). In the following parts we will therefore refer to NMDAab of the IgA and IgM subclasses in our sample as NMDAab.

Table [1](#Tab1){ref-type="table"} compares different demographic characteristics., The UPDRS III score, results of cognitive tests and the frequency of NMDAab between PD patients (*n* = 296) and controls (*n* = 295) as well as following diagnostic subgroups: PD without cognitive impairment (PD-WOC), PD with MCI (PD-MCI), PD with dementia (PD-D) had been compared. Case-control matching resulted in nearly perfect sex matching and minimal albeit significant age difference (\~ 2 years) between PD patients and controls. Since increasing age has repeatedly been associated with an increase in NMDAab antibody frequency we examined the influence of age, using a logistic regression model with NMADab positivity as outcome variable \[[@CR4], [@CR14]\]. NMDAab positivity was related to increasing age in controls (*p* = 0.009, OR = 1.07, 95%CI: 1.02--1.13). However, age had no significant influence on NMDAab positivity in PD patients (*p* = 0.599, OR = 0.987, 95%CI: 0.939--1.039). Therefore, we did not use regression models with age as covariate for all analyses performed within PD patient subgroups only. Among PD patients, the age at examination, the age at PD onset, the duration of PD at the time of examination and the UPDRS III score increased in the order PD-WOC, PD-MCI and PD-D (Table [1](#Tab1){ref-type="table"}). All measures of cognitive performance indicated an increasing cognitive deficit from PD-WOC to PD-MCI and PD-D (Table [1](#Tab1){ref-type="table"}). NMDAab were more frequent in controls (22%) than in PD patients (13%, *p* = 0.003) as well as in controls compared to each of the three PD patient diagnostic subgroups (Table [1](#Tab1){ref-type="table"}). NMDAab frequency did not differ significantly between the diagnostic subgroups (Table [1](#Tab1){ref-type="table"}, *p* = 0.885) and also not comparing PD-WOC against all PD with cognitive impairment (PD-MCI + PD-D, *p* = 0.662) nor comparing PD-WOC against PD-D (*p* = 0.937). Table [2](#Tab2){ref-type="table"} shows the metrics and *p*-values of quantitative tests in NMDAab negative versus NMDAab positive PD patients. Age at examination, age at PD onset and PD duration as well as the cognitive test results did not differ significantly between NMDAab negative and NMDAab positive PD patients (Table [2](#Tab2){ref-type="table"}). Finally, Additional file [1](#MOESM1){ref-type="media"}: Table S1 provides frequencies and titres of NMDAab sub-classes (IgA, IgM) in PD patients, control subjects and the three diagnostic subgroups.Table 1Study metrics for PD and controls as well and diagnostic subgroupsDiagnostic groupValueTestComparison*P*-valuePDPD-WOCPD-MCIPD-DAll controlsMalen (%)chi2all PD vs. Controls0.9747186 (63)89 (59)77 (68)20 (63)185 (63)Mean Sample age in yearsmean/sdt.testall PD vs. Controls0.000768 ± 766 ± 769 ± 573 ± 666 ± 6Age PD onsetmean/sdANOVAPD-WOC, PD-MCI, PD-D0.010360 ± 959 ± 861 ± 863 ± 10naPD durationmean/sdANOVAPD-WOC, PD-MCI, PD-D0.09308.3 ± 5.97.6 ± 5.28.7 ± 5.99.9 ± 7.7naUPDRS IIImedian/madKWPD-WOC, PD-MCI, PD-D3.06E-0621 ± 11.918 ± 10.422 ± 11.931 ± 14.1naMMSEmedian/madKWPD-WOC, PD-MCI, PD-D9.34E-1229 ± 1.529 ± 1.528 ± 1.525 ± 3.0naPANDAmedian/madKWPD-WOC, PD-MCI, PD-D3.40E-1223 ± 5.926 ± 4.522 ± 4.513 ± 7.4naWechsler Memory Scale digit span reverse, number of correct numerical seriesmedian/madKWPD-WOC, PD-MCI, PD-D3.21E-076 ± 1.56 ± 1.55 ± 1.54 ± 3.0naModified Card Sorting Test, Categories completedmedian/madKWPD-WOC, PD-MCI, PD-D4.2E-114 ± 1.55 ± 1.53 ± 1.52 ± 1.5naStroop Test reading colours (s)median/madKWPD-WOC, PD-MCI, PD-D6.67E-0836 ± 6.732 ± 5.938 ± 7.449 ± 14.8naStroop Test naming colours (s)median/madKWPD-WOC, PD-MCI, PD-D1.11E-0653 ± 11.950 ± 8.955 ± 14.162 ± 8.9naStroop Test interference (s)median/madKWPD-WOC, PD-MCI, PD-D9.71E-09101 ± 23.790 ± 19.3105 ± 28.9161 ± 68.9naCERAD Trail Making Test A, time to complete (s)median/madKWPD-WOC, PD-MCI, PD-D2.31E-1345 ± 17.838 ± 10.451 ± 17.896 ± 46.7naCERAD Trail Making Test B, time to complete (s)median/madKWPD-WOC, PD-MCI, PD-D2.31E-13120 ± 63.892 ± 36.3141.0 ± 67.5275 ± 37.1naCERAD word list memory test, sum score of 3 trails, immediate recall (range 0--30)median/madKWPD-WOC, PD-MCI, PD-D4.75E-1119 ± 4.522 ± 4.519 ± 4.514 ± 5.9naCERAD word list, delayed free recall (range 0--10)median/madKWPD-WOC, PD-MCI, PD-D5.66E-117 ± 3.08 ± 1.56 ± 3.04 ± 1.5naPerformance Evaluation System for Seniors (LPS 50+) subtest spatial abilities, sum of correct itemsmedian/madKWPD-WOC, PD-MCI, PD-D3.52E-1318 ± 7.421 ± 4.515 ± 7.45 ± 4.4naNMDA positiven (%)chi2all PD vs. Controls0.003238(13)/258(87)nanana65(22)/230(78)NMDA positiven (%)chi2PD-WOC, PD-MCI, PD-D0.8854na18(12)/132(88)16(14)/98(86)4(13)/28(87)naNMDA positiven (%)chi2PD-WOC vs. (PD-MCI + PD-D)0.6622na18(12)/132(88)20(14)/126(86)naNMDA positiven (%)chi2PD-WOC vs. PD-D0.9372na18(12)/132(88)na4(13)/28(87)naTable 2Comparison of demographic, clinical and cognitive parameters between NMDAab negative and NMDAab positive PD patientsMetric between nmda negative and nmda positive PD patientsValueTest*P*-valueSample agemean/sdt-test0.655Age PD onsetmean/sdt-test0.316PD durationmean/sdt-test0.401UPDRS IIImedian/madMWU0.723MMSEmedian/madMWU0.808PANDAmedian/madMWU0.174Wechsler Memory Scale digit span reverse, number of correct numerical seriesmedian/madMWU0.259Modified Card Sorting Test, Categories completedmedian/madMWU0.325Stroop Test reading colours (s)median/madMWU0.190Stroop Test naming colours (s)median/madMWU0.390Stroop Test interference (s)median/madMWU0.589CERAD Trail Making Test A, time to complete (s)median/madMWU0.075CERAD Trail Making Test B, time to complete (s)median/madMWU0.167CERAD word list memory test, sum score of 3 trails, immediate recall (range 0--30)median/madMWU0.163CERAD word list, delayed free recall (range 0--10)median/madMWU0.308Performance Evaluation System for Seniors (LPS 50+) subtest spatial abilities, sum of correct itemsmedian/madMWU0.070

Discussion {#Sec7}
==========

In this study, NMDAab are not associated with PD or with progression to PD-MCI or PD-D. In contrast, NMDAab are statistically significantly more common in control sera (22%) than in PD patient sera (13% in all PD patients, 12% in PD patients without cognitive impairment). The first of two sizeable previous studies found NMDAab in 2% of PD patients without dementia \[[@CR5]\] and the second one in 8.1% \[[@CR4]\] of all included PD patients while 4.3% \[[@CR5]\] and 8.5% of controls exhibited NMDAab, respectively. These numbers show that the variability in NMDAab frequency between studies is very high. The control subjects in this study were free of self-reported neurological disease. Therefore neurological disease does not account for the high frequency of NMDAab in controls. Age and sex distribution between PD and controls was very similar with a small but statistically significant age difference between groups (Table [1](#Tab1){ref-type="table"}). The high variability of NMDAab frequencies between studies (PD: 2 to 13%, Control: 4.3 to 22%) remains unexplained. All three available studies agree that the frequency of NMDAab in PD patients without dementia is not elevated. However, the study by Doss et al. reports a significantly higher prevalence of NMDAab in PD-D than in PD, which is not found in this study. The PD patients included in this study stem from two sources: the Landscape study focussing on the development of dementia during progression of PD and patients collected at the Department of Neurology of Kiel University. The UPDRS III score at the time of serum sampling and a diagnostic sub-classification into PD-WOC, PD-MCI and PD-D was available for all PD patients. The UPDRS III score showed no significant difference between NMDAab negative and positive PD indicating that the motor symptoms in NMDAab positive PD patients were not more severe than the symptoms of NMDAab negative PD patients. NMDAab were also not significantly more common in PD-D than in PD-WOC or PD-MCI or in PD-WOC versus all PD with cognitive impairment (PD-MCI + PD-D). This finding is in stark contrast to the study by Doss et al. \[[@CR5]\] who found that NMDAab were 10-times more common (20% vs. 2%) in PD-D compared to PD without dementia. It should be taken into account that 2% of PD patients without dementia corresponded 1 of 49 samples and 20% of PD-D patients corresponded to 5 out of 25 samples in the study by Doss et al. \[[@CR5]\]. The corresponding numbers in our study are also small with 18 of 150 NMDAab positive PD patients without cognitive impairment and 20 of 150 NMDAab positive PD patients with any cognitive impairment, albeit much larger than in the previous study. A plethora of cognitive test results was available for the Landscape study. None of cognitive test results differed significantly between NMDAab positive and negative PD patients. Only the subtest "visuospatial functioning" of the Performance Evaluation systems for Seniors (LPS 50+) showed a suggestive difference (*p* = 0.070). However, regarding this and some of the other tests, PD patients with NMDAab in our sample performed slightly better than patients without NMDAab. We conclude that cognitive impairment in PD including multiple markers of cognitive performance is not correlated with NMDAab in our study. We have not formally tested controls for cognitive impairment which might influence the comparisons between cases and controls. Therefore, we think that the most important added value compared to previous studies is the within-case analysis which is not influenced by control selection and did not reveal an association between antibody status and cognitive test results. Strengths of our study are the large sample size of 296 PD patients and 295 controls, the detailed, especially cognitive phenotyping of PD patients from the Landscape study and the high proportion of population based controls from the popgen study as well as the absence of self-reported neurological disease in all controls. Age and sex matching and an analysis of the influence of age on NMDAab status was undertaken to prevent age/sex effects. Despite these precautions we found an unusually high number of NMDAab carriers among controls which might be related to the lack of controls in the Landscape study necessitating the use of popgen controls collected in a different setting. This represents a major weakness of the study.

Conclusions {#Sec8}
===========

We conclude that we did not find a significantly increased frequency of NMDAab in PD patients with cognitive impairment compared to those without it and that NMDAab status is not correlated with the performance in any of the cognitive tests employed in the Landscape study. However, these findings do still not completely rule out a role for NMDAab in PD.

Additional file
===============

 {#Sec9}

Additional file 1:**Table S1.** Antibody subclasses, number of NMDAab positive samples and titres in PD patients, controls and PD diagnostic subgroups. (DOCX 14 kb)

CERAD

:   Consortium to establish a registry for Alzheimer's disease

MCI

:   Mild cognitive impairment

MMSE

:   Mini-Mental-State-Examination

NMDAab

:   Autoantibodies against NMDA-type glutamate receptor

PANDA

:   Parkinson Neuropsychometric Dementia Assessment

PD

:   Parkinson disease

PD-D

:   PD with dementia

PD-MCI

:   PD with MCI

PD-WOC

:   PD without cognitive impairment

UPDRS

:   Unified Parkinson's Disease Rating Scale
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